Nasus Pharma (NSRX) CEO adds 2,900 shares, lifting stake to 156,991

Rhea-AI Filing Summary

Nasus Pharma Ltd Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase of 2,900 Ordinary Shares of NSRX at $3.76 per share on April 22, 2026. After this transaction, he beneficially owns 156,991 shares in total.

This position consists of 24,146 Ordinary Shares and 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days, indicating that the trade is small relative to his overall economic exposure to the company.

Insider Trade Summary

Net Buyer: 2,900 shares ($10,904)

Net Buy 1 txn

Insider Teleman Dan Benjamin

Role Chief Executive Officer

Bought 2,900 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	2,900	$3.76	$11K

Holdings After Transaction: Ordinary Shares — 156,991 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 2,900 shares Purchase price: $3.76 per share Total beneficial ownership: 156,991 shares +2 more

5 metrics

Shares purchased 2,900 shares Open-market purchase on April 22, 2026

Purchase price $3.76 per share Open-market transaction for Ordinary Shares

Total beneficial ownership 156,991 shares Shares beneficially owned after the reported transaction

Ordinary Shares held 24,146 shares Portion of beneficial ownership held as Ordinary Shares

Options exercisable within 60 days 132,845 shares Ordinary Shares issuable upon exercise of outstanding share options

Key Terms

open-market purchase, Ordinary Shares, share options, beneficially owns

4 terms

open-market purchase financial

"transaction_action is described as "open-market purchase" for the Ordinary Shares"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"Consists of: (i) 24,146 ordinary shares, no par value per share ("Ordinary Shares")"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

share options financial

"132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

beneficially owns financial

"After this transaction, he beneficially owns 156,991 shares in total"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teleman Dan Benjamin

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/22/2026		P		2,900	A	$3.76	156,991(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of: (i) 24,146 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.

	/s/ Dan Benjamin Teleman	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nasus Pharma (NSRX) CEO Dan Benjamin Teleman do in this Form 4 filing?

Dan Benjamin Teleman reported an open-market purchase of 2,900 Nasus Pharma Ordinary Shares at $3.76 per share. This filing updates his disclosed ownership and shows a modest increase in his direct economic exposure to NSRX equity.

How many Nasus Pharma (NSRX) shares did the CEO buy and at what price?

The CEO purchased 2,900 Ordinary Shares of Nasus Pharma in an open-market transaction at a price of $3.76 per share. This single trade is the only transaction reported in the Form 4 filing for that date.

What are Dan Benjamin Teleman’s total reported holdings in Nasus Pharma (NSRX) after the transaction?

Following the purchase, Dan Benjamin Teleman beneficially owns 156,991 shares linked to Nasus Pharma. This total includes 24,146 Ordinary Shares plus 132,845 Ordinary Shares that are issuable upon exercise of outstanding share options exercisable within 60 days.

What portion of the Nasus Pharma (NSRX) CEO’s position comes from share options?

Out of the CEO’s 156,991 beneficially owned shares, 132,845 are Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. The remainder, 24,146 shares, are currently held as Ordinary Shares.

Was the Nasus Pharma (NSRX) CEO’s transaction a purchase or sale of shares?

The Form 4 shows a purchase transaction. Dan Benjamin Teleman executed an open-market purchase coded “P,” acquiring 2,900 Ordinary Shares at $3.76 per share, which increased his total reported beneficial ownership in Nasus Pharma.

Does the Nasus Pharma (NSRX) Form 4 show any derivative transactions or option exercises?

The transaction itself is a non-derivative open-market share purchase, not an option exercise. However, a footnote discloses 132,845 Ordinary Shares that are issuable upon exercise of outstanding share options exercisable within 60 days, contributing to the CEO’s beneficial ownership.